Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced the placement of Kurt Gish Ph.D., as Chief Scientific Officer at BioLoomics, a biotechnology company that targets peptide-antibody chimeras to specific compartments inside of diseased cells. Dr Gish will focus on building the company’s pipeline of lysosomal targeting ADCs in oncology to overcome the limitations of poor tumor uptake, which hinders safety and efficacy across the ADC market.
Prior to BioLoomics, Dr. Gish served as Chief Scientific Officer and Founder of Trilo Therapeutics where he pioneered a novel DNA encoded library approach to build D-peptide conjugates to rival traditional ADC modalities. Prior to Trilo, Dr. Gish was an early pioneer in ADCs at AbbVie, investigating novel linkers and payloads, exploring the nature of antigen-independent toxicity and driving two ADC programs into human clinical trials. He serves on the scientific advisory board of the Myeloma Investment Fund of the Multiple Myeloma Research Foundation.
“Kurt Gish is a tremendously talented and highly respected scientist and business leader with a history of driving the development of innovative therapies and treatments,” said Leslie Loveless, CEO and Managing Partner at Slone Partners. “As BioLoomis continues seeking new solutions to unlock the many mysteries of cancer, Dr. Gish will play an important role as part of the company’s leadership team.”
Also Read: Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference
“Kurt is an impressive and accomplished scientist who sits at the intersection of ADCs, peptides, and target discovery/validation. He has a deep understanding of how improper spatial targeting of ADCs has limited the field,” said Doug Chapnick, Founder and CEO of BioLoomis. “With his deep experience in the ADC space, I am confident that Kurt will be invaluable to advancing BioLoomics’s technology to build safer and more efficacious ADCs for both strategic partners and internal programs.”
“BioLoomics is developing incredible technology to deliver more therapeutic drugs directly into cancer cells while minimizing systemic toxicity,” remarked Dr. Gish. “I’m thrilled to join such an innovative team and look forward to getting the best possible treatments to patients who so desperately need them.”
Dr. Gish earned his Ph.D. in Biology from Stanford University and studied molecular immunology during his postdoctoral fellowship at the DNAX Research Institute.
SOURCE: PRWeb